Originally published by our sister publication Gastroenterology & Endoscopy News
The FDA has approved vonoprazan (Voquezna, Phathom) 10-mg tablets for use in patients with nonerosive reflux disease.
This new approval joins prior approvals for the potassium-competitive acid blocker for erosive esophagitis and for Helicobacter pylori eradication when used in combination with antibiotics.
The approval for use in patients with NERD follows positive results from the phase 3 PHALCON-NERD-301 trial (